

David Saadoun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8918282/publications.pdf>

Version: 2024-02-01

243
papers

14,422
citations

12330

69
h-index

24982

109
g-index

248
all docs

248
docs citations

248
times ranked

13844
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077.	27.0	683
2	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213225.	0.9	442
3	Complement receptor 2/CD21 ^{hi} human naive B cells contain mostly autoreactive unresponsive clones. <i>Blood</i> , 2010, 115, 5026-5036.	1.4	399
4	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 209-217.	0.9	273
5	The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 3635-3644.	8.2	259
6	New insights into the pathogenesis of Behçet's disease. <i>Autoimmunity Reviews</i> , 2012, 11, 687-698.	5.8	255
7	Rituximab plus Peg-interferon- α /ribavirin compared with Peg-interferon- α /ribavirin in hepatitis C-related mixed cryoglobulinemia. <i>Blood</i> , 2010, 116, 326-334.	1.4	248
8	Retrospective Analysis of Surgery Versus Endovascular Intervention in Takayasu Arteritis. <i>Circulation</i> , 2012, 125, 813-819.	1.6	238
9	Cryoglobulinemia Vasculitis. <i>American Journal of Medicine</i> , 2015, 128, 950-955.	1.5	229
10	Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. <i>Arthritis and Rheumatism</i> , 2006, 54, 3696-3706.	6.7	227
11	CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. <i>Blood</i> , 2004, 103, 3428-3430.	1.4	207
12	Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. <i>Blood</i> , 2005, 105, 74-76.	1.4	200
13	Spectrum of Cardiac Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 25-34.	1.0	199
14	Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 655-664.	2.9	196
15	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current α-free treatment and future perspectives. <i>Liver International</i> , 2016, 36, 47-57.	3.9	193
16	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Therapeutic Advances in Infectious Disease</i> , 2016, 3, 3-14.	1.8	176
17	Long-Term Outcome of Arterial Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 18-24.	1.0	175
18	PEGylated interferon α 2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2005, 52, 911-915.	6.7	164

#	ARTICLE	IF	CITATIONS
19	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. <i>Circulation</i> , 2017, 136, 1114-1122.	1.6	161
20	Efficacy of Biological-Targeted Treatments in Takayasu Arteritis. <i>Circulation</i> , 2015, 132, 1693-1700.	1.6	157
21	Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. <i>Arthritis Research and Therapy</i> , 2012, 14, R221.	3.5	156
22	Behçet's disease physiopathology: a contemporary review. <i>Autoimmunity Highlights</i> , 2016, 7, 4.	3.9	155
23	Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. <i>Journal of Clinical Investigation</i> , 2010, 120, 4558-4568.	8.2	154
24	CVID-associated TACI mutations affect autoreactive B cell selection and activation. <i>Journal of Clinical Investigation</i> , 2013, 123, 4283-4293.	8.2	153
25	The Spectrum of Type I Cryoglobulinemia Vasculitis. <i>Medicine (United States)</i> , 2013, 92, 61-68.	1.0	150
26	Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2001-2011.	6.7	147
27	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	30.5	143
28	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. <i>Liver International</i> , 2010, 30, 1259-1269.	3.9	139
29	Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782.	0.9	136
30	Anti TNF- α in refractory Takayasu's arteritis: Cases series and review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, 678-684.	5.8	132
31	Increased Risks of Lymphoma and Death Among Patients With Non-Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>Archives of Internal Medicine</i> , 2006, 166, 2101.	3.8	131
32	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. <i>Arthritis and Rheumatology</i> , 2016, 68, 1522-1530.	5.6	131
33	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. <i>Blood</i> , 2010, 116, 4523-4531.	1.4	126
34	Behçet's disease. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 20.	2.7	125
35	Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 153, 49-52.e5.	1.3	125
36	Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2013, 61, 623-637.	1.9	124

#	ARTICLE	IF	CITATIONS
37	Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. <i>Medicine (United States)</i> , 2014, 93, 340-349.	1.0	122
38	Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. <i>Arthritis and Rheumatism</i> , 2008, 58, 604-611.	6.7	115
39	Hepatitis B virus genotypes and extrahepatic manifestations. <i>Journal of Hepatology</i> , 2005, 43, 764-770.	3.7	104
40	Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. <i>Gut</i> , 2018, 67, 2025-2034.	12.1	104
41	Long-Term Outcome of Neuro-Behçet's Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1306-1314.	5.6	102
42	Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. <i>Blood</i> , 2008, 111, 5334-5341.	1.4	101
43	Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1819-1828.	2.0	100
44	Efficacy and tolerability of rituximab with or without PEGylated interferon alpha-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 2531-2540.	6.7	99
45	Chronic Lithium Nephropathy: MR Imaging for Diagnosis. <i>Radiology</i> , 2003, 229, 570-574.	7.3	97
46	Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. <i>Autoimmunity Reviews</i> , 2018, 17, 391-398.	5.8	97
47	Critical role of neutrophil extracellular traps (NETs) in patients with Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1274-1282.	0.9	96
48	Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1748-1757.	6.7	95
49	Peripheral Neuropathies Associated With Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2011, 90, 133-138.	1.0	94
50	Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. <i>Autoimmunity Reviews</i> , 2017, 16, 1254-1264.	5.8	93
51	Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 23-28.	4.3	91
52	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	4.1	91
53	Extrahepatic Manifestations of Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021, 384, 1038-1052.	27.0	90
54	Expansion of Functionally Anergic CD21 ^{low} Marginal Zone-like B Cell Clones in Hepatitis C Virus Infection-Related Autoimmunity. <i>Journal of Immunology</i> , 2011, 187, 6550-6563.	0.8	89

#	ARTICLE	IF	CITATIONS
55	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018, 57, 2200-2212.	1.9	89
56	Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 1337-1345.	7.3	88
57	Cryoglobulinemia: An update in 2019. <i>Joint Bone Spine</i> , 2019, 86, 707-713.	1.6	88
58	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87
59	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
60	PegIFN±/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. <i>Journal of Hepatology</i> , 2015, 62, 24-30.	3.7	86
61	Rituximab in anti-GBM disease: A retrospective study of 8 patients. <i>Journal of Autoimmunity</i> , 2015, 60, 74-79.	6.5	84
62	Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 288-294.	3.4	81
63	Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 152, 2052-2062.e2.	1.3	81
64	Clinical and Morphologic Spectrum of Renal Involvement in Patients With Mixed Cryoglobulinemia Without Evidence of Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2009, 88, 341-348.	1.0	79
65	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. <i>American Journal of Pathology</i> , 2016, 186, 691-700.	3.8	78
66	Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2005, 52, 2917-2925.	6.7	76
67	Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. <i>JAMA Neurology</i> , 2017, 74, 1336.	9.0	76
68	The pathophysiology of HCV induced B-cell clonal disorders. <i>Autoimmunity Reviews</i> , 2007, 6, 581-587.	5.8	75
69	Cryofibrinogenemia: New Insights into Clinical and Pathogenic Features. <i>American Journal of Medicine</i> , 2009, 122, 1128-1135.	1.5	73
70	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
71	Regulatory and Effector T Cell Activation Levels Are Prime Determinants of In Vivo Immune Regulation. <i>Journal of Immunology</i> , 2006, 177, 2167-2174.	0.8	70
72	Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). <i>American Journal of Ophthalmology</i> , 2017, 178, 176-185.	3.3	69

#	ARTICLE	IF	CITATIONS
73	Medium- and Large-Vessel Vasculitis. <i>Circulation</i> , 2021, 143, 267-282.	1.6	68
74	Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. <i>Journal of Rheumatology</i> , 2005, 32, 484-8.	2.0	68
75	Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. <i>Aids</i> , 2005, 19, S128-S134.	2.2	65
76	Ophthalmic manifestations in IgG4-related disease. <i>Medicine (United States)</i> , 2017, 96, e6205.	1.0	65
77	Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 518-526.	4.4	63
78	Peg-IFN α /ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 831-837.	0.9	62
79	Causes and Predictive Factors of Mortality in a Cohort of Patients with Hepatitis C Virus-related Cryoglobulinemic Vasculitis Treated with Antiviral Therapy. <i>Journal of Rheumatology</i> , 2010, 37, 615-621.	2.0	61
80	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. <i>Journal of Autoimmunity</i> , 2019, 96, 35-39.	6.5	61
81	Behçet's Disease and Pregnancy. <i>Arthritis and Rheumatism</i> , 2013, 65, 2450-2456.	6.7	60
82	Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. <i>Journal of Autoimmunity</i> , 2018, 91, 55-60.	6.5	59
83	Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 680-685.	5.8	58
84	Ustekinumab for Behçet's disease. <i>Journal of Autoimmunity</i> , 2017, 82, 41-46.	6.5	58
85	Risk Factors and Prevention of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Autoimmune and Inflammatory Diseases. <i>Chest</i> , 2020, 158, 2323-2332.	0.8	58
86	Behçet's disease in Budd-Chiari syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 104.	2.7	57
87	Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. <i>Rheumatology</i> , 2013, 52, 1635-1641.	1.9	56
88	Hepatitis C virus-induced vasculitis: therapeutic options. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 24-30.	0.9	56
89	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
90	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 752-762.	3.4	56

#	ARTICLE	IF	CITATIONS
91	Targeting JAK/STAT pathway in Takayasu's arteritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 951-959.	0.9	56
92	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0240711.	2.5	54
93	Occult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR Assay. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2106-2108.	3.9	52
94	Ethnicity and association with disease manifestations and mortality in Behçet's disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 42.	2.7	52
95	Sjögren Syndrome-Associated Small Fiber Neuropathy. <i>Medicine (United States)</i> , 2013, 92, e10-e18.	1.0	51
96	Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 1727-1732.	5.6	51
97	Expert opinion on the use of biological therapy in non-infectious uveitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 477-490.	3.1	51
98	IFN- γ induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. <i>Autoimmunity Reviews</i> , 2015, 14, 370-375.	5.8	50
99	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. <i>Blood</i> , 2016, 127, 1509-1512.	1.4	49
100	Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. <i>Autoimmunity Reviews</i> , 2016, 15, 994-1000.	5.8	48
101	Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. <i>Journal of Hepatology</i> , 2004, 41, 1031-1037.	3.7	47
102	Myocarditis in Patients With Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e798.	1.0	47
103	Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 76-84.	1.8	46
104	Pseudotumoural presentation of neuro-Behçet's disease: case series and review of literature. <i>Rheumatology</i> , 2012, 51, 1216-1225.	1.9	45
105	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	6.1	44
106	Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. <i>American Journal of Cardiology</i> , 2013, 111, 265-272.	1.6	43
107	Efficacy of Anti-TNF α in Severe and Refractory Neuro-Behçet Disease. <i>Medicine (United States)</i> , 2016, 95, e3550.	1.0	43
108	Small vessel involvement in Takayasu's arteritis. <i>Autoimmunity Reviews</i> , 2013, 12, 355-362.	5.8	41

#	ARTICLE	IF	CITATIONS
109	Neutrophilâ€Platelet and Monocyteâ€Platelet Aggregates in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1733-1735.	3.4	41
110	Brief Report: Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2203-2208.	5.6	40
111	Longâ€Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients. <i>Journal of the American Heart Association</i> , 2018, 7, e010677.	3.7	40
112	Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: a cross-sectional study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 691-697.	2.9	39
113	Effector T Cells Boost Regulatory T Cell Expansion by IL-2, TNF, OX40, and Plasmacytoid Dendritic Cells Depending on the Immune Context. <i>Journal of Immunology</i> , 2015, 194, 999-1010.	0.8	38
114	Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virusâ€induced mixed cryoglobulinemia vasculitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2897-2907.	6.7	37
115	Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102283.	6.5	36
116	Hepatitis C Virus Infection Induced Vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 30-39.	6.5	35
117	Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 456-465.	1.6	35
118	Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: Clinical and medicoeconomic evaluation of a standardized strategy of the etiological) <i>Tj ETQq0 0 0 rgBT / Overlock 105 Tf 50 377</i>		
119	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
120	Cardiac sarcoidosis: A long term follow up study. <i>PLoS ONE</i> , 2020, 15, e0238391.	2.5	32
121	Antiâ€Tumor Necrosis Factor Î± versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema. <i>Ophthalmology</i> , 2022, 129, 520-529.	5.2	32
122	Severe pulmonary arterial hypertension as initial manifestation of intravascular lymphoma: Case report. <i>American Journal of Hematology</i> , 2005, 79, 46-49.	4.1	31
123	Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1665.	4.8	31
124	Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 218.	3.5	31
125	Findings of Cardiac Magnetic Resonance Imaging in Asymptomatic Myocardial Ischemic Disease in Takayasu Arteritis. <i>American Journal of Cardiology</i> , 2014, 113, 881-887.	1.6	30
126	Clinicopathologic characteristics, treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults. <i>Medicine (United States)</i> , 2016, 95, e3964.	1.0	30

#	ARTICLE	IF	CITATIONS
127	New insights on tuberculous aortitis. <i>Journal of Vascular Surgery</i> , 2017, 66, 209-215.	1.1	30
128	Biotherapies in Uveitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3599.	2.4	30
129	Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases. <i>Current Pharmaceutical Design</i> , 2011, 17, 3781-3785.	1.9	29
130	Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2007, 56, 1315-1324.	6.7	28
131	Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. <i>Gut</i> , 2010, 59, 1709-1715.	12.1	28
132	Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. <i>Joint Bone Spine</i> , 2019, 86, 789-793.	1.6	27
133	French recommendations for the management of Behçet's disease. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 352.	2.7	27
134	Biotherapies in Behçet's disease. <i>Autoimmunity Reviews</i> , 2014, 13, 762-769.	5.8	26
135	Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. <i>Liver International</i> , 2017, 37, 1805-1813.	3.9	26
136	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. <i>Autoimmunity Reviews</i> , 2021, 20, 102729.	5.8	26
137	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
138	Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21 ^{low} B Cells From Patients With Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 298-307.	5.6	24
139	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020, 59, 3807-3816.	1.9	24
140	Systemic Vasculitis in Patients with Hepatitis C Virus Infection with and without Detectable Mixed Cryoglobulinemia. <i>Journal of Rheumatology</i> , 2011, 38, 104-110.	2.0	23
141	Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. <i>Rheumatology</i> , 2012, 51, 2083-2090.	1.9	23
142	TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. <i>Journal of Hepatology</i> , 2019, 71, 908-919.	3.7	23
143	Cryoglobulinemia after the era of chronic hepatitis C infection. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 695-700.	3.4	23
144	Long-Term Outcome and Prognosis Factors of Isolated Aortitis. <i>Circulation</i> , 2020, 142, 92-94.	1.6	22

#	ARTICLE	IF	CITATIONS
145	Central nervous system angitis: a series of 31 patients. <i>Clinical Rheumatology</i> , 2014, 33, 105-110.	2.2	21
146	Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. <i>Journal of Rheumatology</i> , 2020, 47, 896-902.	2.0	21
147	Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094261.	3.2	21
148	French recommendations for the management of Takayasu's arteritis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 311.	2.7	21
149	Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. <i>Autoimmunity Reviews</i> , 2014, 13, 319-326.	5.8	20
150	Sarcoidosis with Takayasu arteritis: a model of overlapping granulomatosis. A report of seven cases and literature review. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 740-745.	1.9	20
151	Cryoglobulinaemia vasculitis in patients coinfecting with HIV and hepatitis C virus. <i>Aids</i> , 2006, 20, 871-877.	2.2	19
152	Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2177-2180.	0.9	19
153	Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study. <i>Journal of Autoimmunity</i> , 2021, 116, 102577.	6.5	19
154	Large-vessel vasculitis in human immunodeficiency virus-infected patients. <i>Journal of Vascular Surgery</i> , 2018, 67, 1501-1511.	1.1	18
155	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <i>Kidney International</i> , 2018, 94, 206-213.	5.2	18
156	Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 509-15.	0.8	18
157	Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-6.	1.6	17
158	Rheumatologic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 455-464.	2.1	17
159	Cryoglobulinemia vasculitis: how to handle. <i>Current Opinion in Rheumatology</i> , 2017, 29, 343-347.	4.3	17
160	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. <i>BMJ Open</i> , 2018, 8, e021037.	1.9	17
161	Prognosis of large vessel involvement in large vessel vasculitis. <i>Journal of Autoimmunity</i> , 2020, 108, 102419.	6.5	17
162	Regulatory T cell/Th17 balance in the pathogenesis of paediatric Behçet disease. <i>Rheumatology</i> , 2021, 61, 422-429.	1.9	17

#	ARTICLE	IF	CITATIONS
163	Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon- α 2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1019-1022.	1.6	16
164	CD21 ^{low} Marginal Zone B Cells Highly Express Fc Receptor-like 5 Protein and Are Killed by Anti-Fc Receptor-like 5 Immunotoxins in Hepatitis C Virus-Associated Mixed Cryoglobulinemia Vasculitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 433-443.	5.6	16
165	Factors influencing the recurrence of arterial involvement after surgical repair in Behçet disease. <i>Journal of Vascular Surgery</i> , 2020, 72, 1761-1769.	1.1	16
166	Cryofibrinogen in Patients with Hepatitis C Virus Infection. <i>American Journal of Medicine</i> , 2008, 121, 624-631.	1.5	15
167	¹⁸ F-fluorodeoxyglucose-positron emission tomography scanning is a useful tool for therapy evaluation of arterial aneurysm in Behçet's disease. <i>Joint Bone Spine</i> , 2013, 80, 420-423.	1.6	15
168	Neuro-ophthalmological manifestations of Behçet's disease. <i>British Journal of Ophthalmology</i> , 2019, 103, 83-87.	3.9	15
169	Myocardial Perfusion Imaging in Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2013, 40, 2052-2060.	2.0	14
170	Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?. <i>Journal of Neurology</i> , 2021, 268, 2458-2465.	3.6	14
171	Interferon signature in giant cell arteritis aortitis. <i>Journal of Autoimmunity</i> , 2022, 127, 102796.	6.5	14
172	Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3577-3581.	0.7	13
173	Approaches to immunosuppression in Behçet's disease. <i>Immunotherapy</i> , 2013, 5, 743-754.	2.0	13
174	Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers. <i>Toxicologic Pathology</i> , 2014, 42, 658-671.	1.8	13
175	Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases. <i>Ocular Immunology and Inflammation</i> , 2015, 24, 1-4.	1.8	13
176	Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. <i>American Journal of Ophthalmology</i> , 2022, 238, 173-180.	3.3	13
177	Treatment of hepatitis C virus-related systemic vasculitis. <i>Journal of Rheumatology</i> , 2005, 32, 2078-82.	2.0	13
178	Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. <i>Autoimmunity Reviews</i> , 2019, 18, 621-626.	5.8	12
179	Pregnancy issues in Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 911-914.	3.4	12
180	Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study. <i>Frontiers in Immunology</i> , 2020, 11, 626792.	4.8	12

#	ARTICLE	IF	CITATIONS
181	Cerebrovascular Ischemic Events in Patients With Takayasu Arteritis. <i>Stroke</i> , 2022, 53, 1550-1557.	2.0	12
182	A strobe multicenter descriptive study of 55 infectious aortitis. <i>Medicine (United States)</i> , 2020, 99, e22422.	1.0	11
183	Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e30-e30.	0.9	11
184	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. <i>Journal of Autoimmunity</i> , 2020, 111, 102454.	6.5	11
185	Immunomodulatory role of Interleukin-33 in large vessel vasculitis. <i>Scientific Reports</i> , 2020, 10, 6405.	3.3	11
186	HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. <i>Journal of Hepatology</i> , 2022, 76, 174-185.	3.7	11
187	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306.	2.5	10
188	Systemic sclerosis and prevalence of monoclonal immunoglobulin. <i>Autoimmunity Reviews</i> , 2014, 13, 1189-1194.	5.8	9
189	Fluorescein and OCT Angiography Features of Takayasu Disease. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 774-780.	1.8	9
190	Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2022, 117, 627-636.	0.4	9
191	Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis. <i>Frontiers in Medicine</i> , 2020, 7, 594133.	2.6	8
192	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Therapie</i> , 2021, 76, 285-295.	1.0	8
193	Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 74-80.	0.2	8
194	Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. <i>Autoimmunity Reviews</i> , 2021, 20, 102783.	5.8	7
195	Mast cells drive pathologic vascular lesions in Takayasu arteritis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 292-301.e3.	2.9	7
196	Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 195-196.	0.8	7
197	Temporal arteritis in IgG4 related disease. <i>Joint Bone Spine</i> , 2021, 88, 105087.	1.6	6
198	Old and New Challenges in Uveitis Associated with Behçet's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2318.	2.4	6

#	ARTICLE	IF	CITATIONS
199	Prognostic Factors and Treatment Efficacy in Spinal Cord Sarcoidosis. <i>Neurology</i> , 2022, 98, .	1.1	6
200	Investigational drugs in systemic vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1049-1061.	4.1	5
201	Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. <i>Autoimmunity Reviews</i> , 2020, 19, 102464.	5.8	5
202	Hepatitis C virus-related vasculitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101575.	1.5	5
203	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. <i>Joint Bone Spine</i> . 2020;87:191-193. <i>Joint Bone Spine</i> , 2021, 88, 105074.	1.6	5
204	Perspectives for immunotherapy in noninfectious immune mediated uveitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 977-989.	3.0	5
205	Correlation between Ultra-Wide-Field Retinal Imaging Findings and Vascular Supra-Aortic Changes in Takayasu Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4916.	2.4	5
206	Mortality associated with Behçet's disease in France assessed by multiple-cause-of-death analysis. <i>Clinical Rheumatology</i> , 2022, 41, 1749-1758.	2.2	5
207	Treatment with Peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia. <i>Journal of Hepatology</i> , 2005, 43, 737.	3.7	4
208	L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: Therapeutic options. <i>Presse Medicale</i> , 2013, 42, 523-527.	1.9	4
209	HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e59-e59.	0.9	4
210	Risk factors for vascular liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 410-419.	1.5	4
211	Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). <i>PLoS ONE</i> , 2020, 15, e0228918.	2.5	4
212	Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: anti-viral therapy vs rituximab. <i>Rheumatology</i> , 2006, 45, 783-784.	1.9	3
213	Prise en charge de la maladie de Takayasu. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 229-235.	0.0	3
214	Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 651-657.	3.0	3
215	Neuroinflammatory disorders and mastocytosis: A possible association?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2878-2881.e1.	3.8	2
216	Strategies to prevent persistent or relapsed mixed cryoglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 137-143.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Women and Pregnancy in Thromboangiitis Obliterans. Journal of Vascular Research, 2021, 58, 1-3.	1.4	2
218	Virus-Associated Vasculitides: An Update. Current Immunology Reviews, 2013, 9, 2-12.	1.2	2
219	Overview of Imaging in Adult- and Childhood-onset Takayasu Arteritis. Journal of Rheumatology, 2022, 49, 346-357.	2.0	2
220	Virus-Associated Vasculitides. Current Immunology Reviews, 2011, 7, 443-451.	1.2	1
221	Reply. Arthritis and Rheumatism, 2013, 65, 3007-3008.	6.7	1
222	Current and future therapeutic strategies for treating mixed cryoglobulinemia. Expert Opinion on Orphan Drugs, 2014, 2, 381-390.	0.8	1
223	Moving towards new treatments for vasculitis. Expert Opinion on Emerging Drugs, 2016, 21, 239-242.	2.4	1
224	Absence of HCV RNA in serum and cryoprecipitate of patients with persisting mixed cryoglobulinaemia vasculitis after direct-acting antiviral agents. GastroHep, 2019, 1, 134-137.	0.6	1
225	Response. Chest, 2020, 158, 2705-2706.	0.8	1
226	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. Archives of Cardiovascular Diseases, 2022, 115, 96-96.	1.6	1
227	Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
228	Vascular Behçet's disease: a comparative study from Turkey and France. Clinical and Experimental Rheumatology, 0, , .	0.8	1
229	La tomographie par Émission de positons au 18F-fluorodÉoxyglucose permet lâ€™Évaluation des anÉvrismes artÉriels dans la maladie de Behçet. Revue Du Rhumatisme (Edition Francaise), 2013, 80, 308-311.	0.0	0
230	Cryoglobulinemia vasculitis. Hematologie, 2015, 21, 193-197.	0.0	0
231	Response to: Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug. Annals of the Rheumatic Diseases, 2017, 76, e6.	0.9	0
232	Reply. American Journal of Ophthalmology, 2017, 179, 208-209.	3.3	0
233	Reactive oxygen species and TNF-Î±: the interplay between obstructive sleep apnea and Behçet's disease. Sleep and Breathing, 2020, 25, 1553-1554.	1.7	0
234	Correspondance on Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Annals of the Rheumatic Diseases, 2020, , annrhumdis-2020-219566.	0.9	0

#	ARTICLE	IF	CITATIONS
235	Manifestations extra h�patiques li�es � l'infection chronique par le virus de l'h�patite C et leurs traitements.. Bulletin De L'Academie Nationale De Medecine, 2006, 190, 123-137.	0.0	0
236	Cryoglobulinemic Vasculitis. , 2018, , 355-363.		0
237	The Prognosis of Beh�set Syndrome. , 2020, , 243-260.		0
238	Reply. Ophthalmology, 2022, , .	5.2	0
239	Title is missing!. , 2020, 15, e0240711.		0
240	Title is missing!. , 2020, 15, e0240711.		0
241	Title is missing!. , 2020, 15, e0240711.		0
242	Title is missing!. , 2020, 15, e0240711.		0
243	Vascular Beh�set's disease: a comparative study from Turkey and France.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0